Apimeds Pharmaceuticals US, Inc. (APUS)
NYSEAMERICAN: APUS · Real-Time Price · USD
1.780
+0.062 (3.60%)
At close: Jun 27, 2025, 4:00 PM
1.779
-0.001 (-0.04%)
After-hours: Jun 27, 2025, 8:00 PM EDT
APUS Market Cap
APUS has a market cap or net worth of $20.60 million as of June 27, 2025.
Market Cap
20.60M
Enterprise Value
21.32M
1-Year Change
n/a
Ranking
Category
Stock Price
1.78
Market Cap Chart
Since the IPO on May 9, 2025, APUS's market cap has decreased from $25.45M to $20.60M, a decrease of -19.04%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 26, 2025 | 19.89M | 3.51% |
| Jun 25, 2025 | 19.22M | 0.61% |
| Jun 24, 2025 | 19.10M | -1.20% |
| Jun 23, 2025 | 19.33M | 2.45% |
| Jun 20, 2025 | 18.87M | -8.43% |
| Jun 18, 2025 | 20.61M | -3.26% |
| Jun 17, 2025 | 21.30M | -4.17% |
| Jun 16, 2025 | 22.23M | 4.92% |
| Jun 13, 2025 | 21.18M | -1.07% |
| Jun 12, 2025 | 21.41M | 1.08% |
| Jun 11, 2025 | 21.18M | -0.54% |
| Jun 10, 2025 | 21.30M | -2.13% |
| Jun 9, 2025 | 21.76M | -2.59% |
| Jun 6, 2025 | 22.34M | 1.58% |
| Jun 5, 2025 | 21.99M | 1.06% |
| Jun 4, 2025 | 21.76M | -4.08% |
| Jun 3, 2025 | 22.69M | 8.89% |
| Jun 2, 2025 | 20.84M | 2.86% |
| May 30, 2025 | 20.26M | 1.16% |
| May 29, 2025 | 20.03M | 5.49% |
| May 28, 2025 | 18.98M | -8.89% |
| May 27, 2025 | 20.84M | -0.55% |
| May 23, 2025 | 20.95M | -0.55% |
| May 22, 2025 | 21.07M | 0.83% |
| May 21, 2025 | 20.89M | -2.43% |
| May 20, 2025 | 21.42M | 3.42% |
| May 19, 2025 | 20.71M | 5.29% |
| May 16, 2025 | 19.67M | -1.73% |
| May 15, 2025 | 20.01M | -6.99% |
| May 14, 2025 | 21.52M | 6.29% |
| May 13, 2025 | 20.24M | -3.31% |
| May 12, 2025 | 20.94M | -17.73% |
| May 9, 2025 | 25.45M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 696.15B |
| Johnson & Johnson | 366.71B |
| AbbVie | 322.03B |
| Novo Nordisk | 304.96B |
| UnitedHealth Group | 280.41B |
| Novartis AG | 235.85B |
| Abbott Laboratories | 233.80B |
| AstraZeneca | 217.42B |